1. 1 BioSciCon, Inc. MarkPap® Platform Technology A guide to the Web Site www.bioscicon.com 2010

2. 2 A guide to the Web Site www.bioscicon.com www.bioscicon.com This is simplified presentation about the MarkPap platform technology and its application to serve as a guide to navigate better throughout the BioSciCon’s Web Site www.bioscicon.com.www.bioscicon.com Please click on the blue link provided on slides to learn more about the subject you are interested in.

3. BioSciCon Consortium of Companies BioSciCon, Inc, the parent R&D corporation for a proprietary, platform MarkPap® technology for cervical cancer prevention www.bioscicon.comwww.bioscicon.com MarkPap LLC, organized for commercialization of the technology (marketing, distribution and sale ) MarkPap Pacific LLC, incorporated specifically for commercialization in greater Pacific Area The Global Academy for Women’s Health, Inc, an independent non-profit dedicated to women’s health education More.. www.markpap.com/index.htmlwww.markpap.com/index.html

4. 4 History & Organizational Structure 1998 – BIOSCICON, INC. R&D 2005 – MARKPAP, LLC COMMERCIALIZATION 2007 – GLOBAL ACADEMY FOR WOMEN’S NON-PROFIT 2007 – MARKPAP PACIIFIC, LLC CHINA BUSINESS 1996 – BIOMEDICAL SCIENCE CONSULTING, INC.

5. 5 Cervical Cancer is preventable Cervical cancer is second to the breast cancer cause of women deaths from malignant diseases world-wide. Currently, there are 500,000 new cases of cervical cancer each year, and about 250,000 die from this preventable disease. In the US, about 20% of 100M women at risk do not take regular Pap test and 4,000 die. However, cervical cancer is preventable IF detected on time. Cytological screening (Pap test) remains the best cervical cancer prevention. More… www.bioscicon.com/publicinformation.html www.bioscicon.com/publicinformation.html

6. 6 WORLD Problem At risk: 2 B Protected with Pap 150 M or about 10% The number in developing countries increased recently to about 80 M Pap tests or about 5%. Other technologies Screen & treat VIA HPV Vaccination

7. 7 The Problem Existing Pap Test Technology:  Costly: Increasing insurance costs in US and prohibitively expensive in developing countries  Infrastructure: required, with qualified professionals (cytotechnologists/pathologists) Insufficient Reliability: (>15% false negatives) Slow: Takes weeks to obtain normal results Requires visiting a doctor and it is invasive, which leads to fewer women being tested

8. 8 The Solution MarkPap® Test is the solution: Less costly: Priced >25% less than Pap test. MarkPap Self and MarkPap Digital make the infrastructure affordable for developing countries. More reliable: <5% false negatives. Less Invasive: MarkPap Self, leading to increased use by all women. Timely: Results within hours (MarkPap Digital). Better controlled: QC/QA with control slides and less liability for the laboratory.

9. 9 How MarkPap Test can do this? The proprietary biomarker is a powerful means to make the test less expensive, more amenable for telecytopathology and to open the possibility for home self- sampling. More… www.bioscicon.comwww.bioscicon.com

10. 10 MarkPap® Platform Technology MarkPap is a a trademark for a patented technology that includes instruments, medical devices, reagents (in vitro diagnostics), controls and procedures and instructions which, in different combinations, are intended to improve the quality of life of healthy women relieving them from fear of cervical cancer risk.

11. 11 MarkPap® platform technology illustrated We have a proprietary technology which is based upon a chemical biomarker positive only in abnormal cells, and always negative in normal cells. This distinction makes the method superior over all competitors. More…. www.bioscicon.com/gallery.html l

12. 12 MarkPap® platform technology illustrated. An ancillary method to Pap test Abnormal specimen, ASC-H. Three small abnormal (red) cells among several normal cells. Screening magnification (left). Diagnostic magnifications (right). Abnormal cells cannot be missed!

13. 13 MarkPap® Advantages Unique biomarker makes possible an instant and simultaneous detection of cervical dysplasia and HPV disease Accurate (diagnostic sensitivity >90%, low FN rates) Fast (results within hours of sampling) Affordable (low cost of supplies and labor) May be used for primary cervical cancer screening and for pre-screening for HPV

14. 14 THE PRESENCE of the BIOMARKER MAKES a Difference MORE ACCURATE, FASTER, LESS EXPENSIVE www.bioscicon.com/publications.html www.bioscicon.com/professionalinformation.html TELEMEDICINE: The marker can be seen by less-trained technician, who transmits images of suspect cells in the laboratory for final diagnosis (TelePap: MarkPap® Digital, MarkPap® Wireless) www.bioscicon.com/productsindev.html www.bioscicon.com/pressrelease.html PROSPECTIVE FOR HOME PAP TEST www.bioscicon.com/productindev/html and www.bioscicon.com/pressrelease.html www.bioscicon.com/publications.html (31,35,37,40),

15. 15 CONTRIBUTION Mass cervical cancer screening worldwide: Huge societal benefit saving women’s lives from preventable cancer, and enormous market with incredible potential for profit (2B women at risk)

16. 16 Products for Sale: Subject to US export and local import regulations 1. MPK: Research Kit 12 individual reagents control slides 2. MPS: Cell preservative solution: 3. Individual reagents from the Kit 4. Manual Procedure 5. MPD: MarkPap Digital-- Telecytopathology Instruments and software for distant evaluation 5. MPSCK: Home Pap Kit (Avail. 2011) 8 individual device

17. 17 MarkPap Research Kit

18. 18 MarkPap Accessories

19. 19 More on MarkPap Products www.bioscicon.com//markpapproducts.htmll www.bioscicon.com/markpaptest.html www.bioscicon.com/markpapresearchkit. html www.bioscicon.com/markpapsolution.html www.bioscicon.com/productsindev.html www.bioscicon.com/pressrelease.html www.markpap.com

20. 20 MarkPap Digital Telelcytopathology System Image acquisition Unit Image forwarding Image and data processing UnitImage evaluation Unit Reporting back

21. 21 IT Telehealth Center: Architecture www.bioscicon.com/productsindev.htmlwww.bioscicon.com/productsindev.html Local Center Design ACQUISITION- REPORT FORM

22. 22 Our MPD Workstation

23. 23 MarkPap Pacific Featured MarkPap Pacific, LLC (MPPLLC) and our recenty signed Trade Agreement with China to bring MarkPap test to China market and use our telehealth services, appeared in Washington Post on December 28, 2009.

24. 24 MarkPap® Wireless: Our recent focus We are currently working on the use of cell phone cameras in the transmission of images from the remote sites. In many parts of the world where computers are not available or affordable, cell phones could substitute the computers. We are working on the development of an Universal Adapter to connect any cell phone any microscope. More... www.bioscicon.com/pressrelease.html

25. 25 Future MarkPapSelf Digital/Wireless In practice, MarkPap Self and MarkPap Digital would allow women to take the sample at home and to mail it to the nearby laboratory. In this laboratory a low-trained technician or nurse can stain the slide using easy-to-use MarkPap Kit. The same person examines the slide under the microscope and searches for “red” cells only. The images of those cells are captured with a digital camera or cell phone camera and transmitted for evaluation. The result may be sent back electronically within hours.. More… www.bioscicon.com/publications.html (40) www.bioscicon.com/publications.html

26. 26 The New Book, Springer 2008

27. 27 More about The Book www.bioscicon.com/publications.html www.amazon.com www.markpap.com Education is the essential part in introducing and successful implementation of a new technologies.

28. 28 Contacts Nenad Markovic, MD, PhD Olivera Markovic, MD, PhD Oleg Panashchenko, PhD Jane Jing, MBA www.bioscicon.com/contact.html